Psilocybin-assisted Treatment for Cannabis Use Disorder

This open-label, proof-of-concept trial (n=12) will evaluate the therapeutic potential of psilocybin in individuals with Cannabis Use Disorder (CUD). Participants will undergo a 12-week treatment course, including two psilocybin (25mg or 35mg) sessions with psychological support, followed by assessments at three and six months post-treatment.

The study, conducted by Johns Hopkins University, involves preparatory cognitive behavioural therapy (CBT) before administering a 25 mg dose of psilocybin in week 5 and either another 25 mg or an increased 35 mg dose in week 7. Follow-up integration meetings will take place within three days after each session, with weekly support continuing throughout the study.

Researchers will assess cannabis use reduction using self-reported data and biomarkers, alongside secondary measures such as depression and sleep quality. The study is set to run from November 2024 to September 2026.

Topic Addiction
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.